NONOF - Eli Lilly posts Q3 beat on diabetes drugs; pushes back Alzheimer's prospects
2023-11-02 07:19:05 ET
More on Eli Lilly
- Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore
- Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
- Eli Lilly: Do Not Chase This Stock Over The Cliff
- Eli Lilly Non-GAAP EPS of $0.10 misses by $0.77, revenue of $9.49B beats by $500M
- Eli Lilly Q3 earnings on deck with GLP-1 drugs in focus
For further details see:
Eli Lilly posts Q3 beat on diabetes drugs; pushes back Alzheimer’s prospects